Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes

Nathaniel J. Hogrebe; Matthew Ishahak; Jeffrey R. Millman

doi:10.1016/j.stem.2023.04.002

Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes

Nathaniel J. Hogrebe, Matthew Ishahak, Jeffrey R. Millman

Research output: Contribution to journal › Review article › peer-review

54 Scopus citations

Abstract

The generation of islet-like endocrine clusters from human pluripotent stem cells (hPSCs) has the potential to provide an unlimited source of insulin-producing β cells for the treatment of diabetes. In order for this cell therapy to become widely adopted, highly functional and well-characterized stem cell-derived islets (SC-islets) need to be manufactured at scale. Furthermore, successful SC-islet replacement strategies should prevent significant cell loss immediately following transplantation and avoid long-term immune rejection. This review highlights the most recent advances in the generation and characterization of highly functional SC-islets as well as strategies to ensure graft viability and safety after transplantation.

Original language	English
Pages (from-to)	530-548
Number of pages	19
Journal	Cell Stem Cell
Volume	30
Issue number	5
DOIs	https://doi.org/10.1016/j.stem.2023.04.002
State	Published - May 4 2023

Keywords

CRISPR
SC-islets
bioreactors
clinical trials
critical quality attributes
cryopreservation
diabetes
differentiation
distribution
encapsulation
immune tolerance
insulin
pancreas
safety
scale-up
single-cell sequencing
stem cells
stress
therapy
transplantation

Access to Document

10.1016/j.stem.2023.04.002

Cite this

@article{82672eb002e7403f8cbbd9c181a4f48f,

title = "Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes",

abstract = "The generation of islet-like endocrine clusters from human pluripotent stem cells (hPSCs) has the potential to provide an unlimited source of insulin-producing β cells for the treatment of diabetes. In order for this cell therapy to become widely adopted, highly functional and well-characterized stem cell-derived islets (SC-islets) need to be manufactured at scale. Furthermore, successful SC-islet replacement strategies should prevent significant cell loss immediately following transplantation and avoid long-term immune rejection. This review highlights the most recent advances in the generation and characterization of highly functional SC-islets as well as strategies to ensure graft viability and safety after transplantation.",

keywords = "CRISPR, SC-islets, bioreactors, clinical trials, critical quality attributes, cryopreservation, diabetes, differentiation, distribution, encapsulation, immune tolerance, insulin, pancreas, safety, scale-up, single-cell sequencing, stem cells, stress, therapy, transplantation",

author = "Hogrebe, {Nathaniel J.} and Matthew Ishahak and Millman, {Jeffrey R.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Author(s)",

year = "2023",

month = may,

day = "4",

doi = "10.1016/j.stem.2023.04.002",

language = "English",

volume = "30",

pages = "530--548",

journal = "Cell Stem Cell",

issn = "1934-5909",

number = "5",

}

TY - JOUR

T1 - Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes

AU - Hogrebe, Nathaniel J.

AU - Ishahak, Matthew

AU - Millman, Jeffrey R.

PY - 2023/5/4

Y1 - 2023/5/4

N2 - The generation of islet-like endocrine clusters from human pluripotent stem cells (hPSCs) has the potential to provide an unlimited source of insulin-producing β cells for the treatment of diabetes. In order for this cell therapy to become widely adopted, highly functional and well-characterized stem cell-derived islets (SC-islets) need to be manufactured at scale. Furthermore, successful SC-islet replacement strategies should prevent significant cell loss immediately following transplantation and avoid long-term immune rejection. This review highlights the most recent advances in the generation and characterization of highly functional SC-islets as well as strategies to ensure graft viability and safety after transplantation.

AB - The generation of islet-like endocrine clusters from human pluripotent stem cells (hPSCs) has the potential to provide an unlimited source of insulin-producing β cells for the treatment of diabetes. In order for this cell therapy to become widely adopted, highly functional and well-characterized stem cell-derived islets (SC-islets) need to be manufactured at scale. Furthermore, successful SC-islet replacement strategies should prevent significant cell loss immediately following transplantation and avoid long-term immune rejection. This review highlights the most recent advances in the generation and characterization of highly functional SC-islets as well as strategies to ensure graft viability and safety after transplantation.

KW - CRISPR

KW - SC-islets

KW - bioreactors

KW - clinical trials

KW - critical quality attributes

KW - cryopreservation

KW - diabetes

KW - differentiation

KW - distribution

KW - encapsulation

KW - immune tolerance

KW - insulin

KW - pancreas

KW - safety

KW - scale-up

KW - single-cell sequencing

KW - stem cells

KW - stress

KW - therapy

KW - transplantation

UR - http://www.scopus.com/inward/record.url?scp=85153795478&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2023.04.002

DO - 10.1016/j.stem.2023.04.002

M3 - Review article

C2 - 37146579

AN - SCOPUS:85153795478

SN - 1934-5909

VL - 30

SP - 530

EP - 548

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 5

ER -

Developments in stem cell-derived islet replacement therapy for treating type 1 diabetes

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this